Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise NLR kinetics in patients with advanced solid tumours treated with PD-1/PD-L1 inhibitors.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur. J. Cancer

Title: European journal of cancer (Oxford, England : 1990)

Publisher: Elsevier BV

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): Jan 2018

Volume: 89

Affiliations

[1 ] The Drug Development Unit, Institute of Cancer Research and the Royal Marsden Hospital, Downs Road, Sutton, UK.

[2 ] The Drug Development Unit, Institute of Cancer Research and the Royal Marsden Hospital, Downs Road, Sutton, UK; CHU de Québec - Université Laval, Quebec City, Canada.

[3 ] The Drug Development Unit, Institute of Cancer Research and the Royal Marsden Hospital, Downs Road, Sutton, UK; START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain.

[4 ] START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain.

[5 ] Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Australia.

[6 ] Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK.

[7 ] Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Australia; La Trobe University School of Cancer Medicine, Melbourne, Australia; Department of Medicine, University of Melbourne, 145 Studley Road, Heidelberg, Victoria 3084, Australia.

[8 ] The Drug Development Unit, Institute of Cancer Research and the Royal Marsden Hospital, Downs Road, Sutton, UK. Electronic address: Juanita.lopez@icr.ac.uk.

Article

Publisher Item ID: S0959-8049(17)31409-0

DOI: 10.1016/j.ejca.2017.11.012

PubMed ID: 29227818

SO-VID: f40a8a8a-1578-4903-9295-d76c2a370606

History

Keywords: PD-1 inhibitors,Neutrophil-lymphocyte ratio,Phase I trials

Data availability:

Keywords: PD-1 inhibitors, Neutrophil-lymphocyte ratio, Phase I trials

Comments

Comment on this article

scite_

Cited by 40

See all cited by